 | | Vol. 12.02 – 22 January, 2021 |
| |
|
|
| Scientists found that Toll-like receptor 2 (TLR2) was highly abundant in the endothelium within various tissues using TLR2-IRES-EGFP reporter mice and was required for proinflammatory endothelial cell function.
[Science Signaling] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists.
[Journal of Medicinal Chemistry] |
|
|
|
| Researchers demonstrated for the first time that Tadalafil can significantly modulate androgen receptor expression and activity, Cyp19a1 and ERβ expression in prostate cancer cells, suggesting a specific effect of these proteins.
[International Journal of Molecular Sciences] |
|
|
|
| The authors investigated the effects of ten different patient‐derived fibroblast lines on the 3D morphogenesis of prostate cancer cells growing on a viscous substrate in vitro.
[Journal of Cellular Biochemistry] |
|
|
|
| Scientists investigated the function and mechanism underlying how miR-541-3p modulates the radiosensitivity of prostate cancer cells by regulating HSP27.
[Cell Death Discovery] |
|
|
|
| Researchers investigated the roles of U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1) in the resistance to anti-androgen treatment in prostate cancer and its underlying mechanism.
[Biochemical and Biophysical Research Communications] |
|
|
|
| The authors shed light on the studies that explored the potential role of Wiskott-Aldrich syndrome protein (WASP) and WASP family verprolin homologous protein (WAVE) family of proteins in invasion and metastasis of prostate cancer.
[Protoplasma] |
|
|
|
| Investigators found the level of small nucleolar RNA host gene 1 (SNHG1) was significantly upregulated in prostate cancer tissues and cells. Knockdown of SNHG1 significantly suppressed proliferation, migration and invasion and promoted cell apoptosis in prostate cancer cells.
[Anti-Cancer Drugs] |
|
|
|
|
| The authors review promising immunotherapies in development and ongoing trials for metastatic castration-resistant prostate cancer (mCRPC). These novel trials will build on past experiences and promise to usher a new era to treat patients with mCRPC.
[Cancers] |
|
|
|
| It has proved difficult to isolate quiescent stem cells as a physical entity. Recent single-cell RNAseq studies on several adult tissues including ovary, prostate, and cardiac tissues have not been able to detect stem cells. Thus, it has been postulated that adult cells dedifferentiate to stem-like state to ensure regeneration and can be defined as cells capable to replace lost cells through mitosis.
[Stem Cell Research & Therapy] |
|
|
|
|
| Forma Therapeutics Holdings, Inc. announced that the first patient has been dosed in a Phase I clinical trial evaluating FT-7051, a selective inhibitor of CBP/p300, a known co-activator of the androgen receptor in men with metastatic castration-resistant prostate cancer.
[Forma Therapeutics Holdings, Inc.] |
|
|
|
|
| February 3 – 5, 2021
Virtual |
|
|
|
|
|
| | Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| | Novo Nordisk – Copenhagen, Denmark |
|
|
|
| | STEMCELL Technologies, Inc. – Burnaby, British Columbia, Canada |
|
|
|
| | Institute of Pharmacology and Structural Biology – Toulouse, France |
|
|
|
| | Medical University of Gdańsk – Gdańsk, Poland |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
